【摘要】 目的 了解2021年北京市中关村地区高脂血症患者降脂药的使用情况，同时对当年高脂血症人群的基因检测结果进行分析，为中关村地区高脂血症人群合理用药提供依据。方法 通过医院信息系统，对2021年中关村医院高脂血症患者降脂药的使用情况分类汇总并进行分析，同时分析人群敏感基因与降脂药使用情况的关系。结果 2021年本院治疗高脂血症的药物使用最多的是阿托伐他汀，其销售金额和用药频度（DDDs）均排名第一位；ApoE基因检测结果提示携带大众基因型的患者占比最高，SLCO1B1基因检测结果提示携带正常代谢基因型的患者占比最高。结论 在服用降脂药前需要对APOE和SLCO1B1基因进行检测，预测药物效果的同时预判不良反应发生率。更多还原

【Abstract】 Objective To analyze the use of hypolipidemic drug in 2021 of Zhongguancun, and the genetic detection results of the hyperlipidemia population in that year, to provide a basis for rational drug use in the population with hyperlipidemia in Zhongguancun. Methods The use of hypolipidemic drug in patients with hyperlipidemia in 2021 Zhongguancun Hospital was classified and analyzed through the hospital information system, and the relationship between the population sensitive genes and the use of hypolipidemic drug was analyzed. Results In 2021, atorvastatin is the most used drug in the treatment of hyperlipidemia in our hospital, and its sales amount and DDDs rank first.The results of ApoE gene test indicated that the proportion of patients carrying the common genotype was the highest, and the results of SLCO1B1 gene test indicated that the proportion of patients carrying the normal genotype was the highest. Conclusion Before taking lipid-lowering drugs, APOE and SLCO1B1 genes need to be detected to predict the effect of drugs and predict the incidence of adverse reactions.更多还原